ArticleEULAR rheumatology open2026
Evaluation of the use of different forms of medical cannabis in the treatment of fibromyalgia: a systematic review.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To systematically review, based on randomised controlled trials (RCTs), some forms of medical cannabis (nabilone, tetrahydrocannabinol-rich oil, and Bediol) in the treatment of fibromyalgia syndrome (FMS). Methods: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for systematic reviews (SRs), the PICO strategy was delimited, and articles with entry terms (medical subject headings) referring to 'medicinal cannabis' and 'fibromyalgia' were searched in the following databases: Medline, via PubMed; Embase; Central, via Cochrane; and Scopus, via Elsevier. The inclusion criteria were as follows: (1) patients of any age, gender, or ethnicity diagnosed with fibromyalgia according to the criteria of the American College of Rheumatology (ACR 1990, 2010, or 2016); (2) undergoing treatment with some type of medical cannabis, regardless of the route of administration, dosage, or duration of treatment (except single dose), compared with current therapy or placebo; and (3) RCTs, blinded or not, published in any language, without time restriction. Results: Only 4 articles were eligible for the production of this SR. From them, it was not possible to infer the real impact after the use of 3 forms of medical cannabis (alone or associated with another therapy) on disease, pain, or insomnia. Conclusions: It is not possible to conclude whether different forms of medical cannabis are an effective and safe therapeutic option for the treatment of FMS symptoms, with tolerable adverse effects. This prescription should be made individually for each patient.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.